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Summary
 
We examined the roles of cell- and antibody-mediated immunity in urease vaccine–induced
protection against 
 
Helicobacter pylori
 
 infection. Normal and knockout mice deficient in major
histocompatibility complex (MHC) class I, MHC class II, or B cell responses were mucosally
immunized with urease plus 
 
Escherichia coli
 
 heat-labile enterotoxin (LT), or parenterally immu-
nized with urease plus aluminum hydroxide or a glycolipid adjuvant, challenged with 
 
H. pylori
 
strain X47-2AL, and 
 
H. pylori
 
 organisms and leukocyte infiltration in the gastric mucosa quan-
tified. In an adjuvant/route study in normal mice, there was a direct correlation between the
level of protection and the density of T cells recruited to the gastric mucosa. In knockout stud-
ies, oral immunization with urease plus LT protected MHC class I knockout mice [
 
b
 
2
 
-micro-
globulin (
 
2
 
/
 
2
 
)] but not MHC class II knockout mice [I-A
 
b
 
 (
 
2
 
/
 
2
 
)]. In B cell knockout mice
[
 
m
 
MT (
 
2
 
/
 
2
 
)], vaccine-induced protection was equivalent to that observed in immunized
wild-type (
 
1
 
/
 
1
 
) mice; no IgA
 
1
 
 cells were detected in the stomach, but levels of CD4
 
1
 
 cells
equivalent to those in the wild-type strain (
 
1
 
/
 
1
 
) were seen. These studies indicate that pro-
tection of mice against 
 
H. pylori
 
 infection by immunization with the urease antigen is depen-
dent on MHC class II–restricted, cell-mediated mechanisms, and antibody responses to urease
are not required for protection.
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H
 
elicobacter pylori
 
, a gram-negative, spiral bacterium that
colonizes the gastric mucosa, is the principal cause of
chronic gastritis, peptic ulcer disease, and gastric adenocar-
cinoma in humans (1, 2). The development of vaccines to
prevent 
 
H. pylori
 
–associated diseases will be facilitated by an
understanding of the immune mechanisms responsible for
protection. Mucosal immunization with recombinant 
 
H.
pylori
 
 urease administered with the mucosal adjuvant 
 
Esche-
richia coli
 
 heat-labile enterotoxin (LT)
 
1
 
 protects mice against
challenge with 
 
H. pylori
 
, reducing bacterial density by
 
z
 
100-fold (3). Efforts to identify specific mechanisms or
cells responsible for protection using a number of 
 
Helico-
bacter
 
 antigens have failed to identify conclusively correlates
of immunity (4–9). Immunized animals develop antigen-
specific serum IgG and IgA, intestinal and salivary IgA, and,
after challenge, a local (gastric) cellular and antibody re-
sponse (3, 5, 10). Protection is also associated with the
presence of CD4
 
1
 
 cells and CD8
 
1
 
 cells in the gastric mu-
cosa (3, 11), and reductions in bacterial load can be
achieved in the absence of active immunization by adop-
tive transfer of T cells from immunized donor mice, sug-
gesting that cell-mediated immune responses play a major
role in protection in this species (12).
Other than mucosal immunization with bacterial anti-
gens combined with LT or cholera toxin (3–13), few im-
munization regimens have been explored as a means to
study the mechanisms of protection against 
 
H. pylori.
 
 Sub-
cutaneous immunization with urease plus several different
parenteral adjuvants generated high levels of serum IgG and
showed various degrees of protection against 
 
Helicobacter fe-
 
1
 
Abbreviations used in this paper:
 
 
 
b
 
2
 
m, 
 
b
 
2
 
-microglobulin; H & E, hematox-
ylin and eosin; IEL, intraepithelial lymphocytes; IN, intranasal; LT, 
 
Esch-
erichia coli
 
 heat-labile toxin; urease-ACC, urease-specific antibody–con-
taining cells.
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lis
 
 or 
 
H. pylori
 
 (5, 14), whereas intranasal (IN) immuniza-
tion with urease without adjuvant generated moderate lev-
els of serum IgG, salivary IgA, and fecal IgA, but was not
protective (15). These findings demonstrated that although
appreciable antibody responses can be generated without a
mucosal adjuvant, protective immunity mediated via urease
immunization can only be achieved in the presence of a
mucosal or parenteral adjuvant. The lack of protection in
the absence of a suitable mucosal adjuvant suggested that
antibody may not be an essential mediator of protection.
Recent developments in gene knockout technology
have produced a variety of experimental mouse models to
study mechanisms of immunity and their roles in infectious
diseases. Mice in which the I-A gene has been disrupted
lack MHC class II molecules, are deficient in CD4
 
1
 
 T
cells, and have impaired cellular and antibody-mediated
immunity (16, 17). Mice in which the 
 
b
 
2
 
-microglobulin
(
 
b
 
2
 
m) molecule is lacking are deficient in MHC class I
molecules, fail to differentiate normal numbers of CD8
 
1
 
 T
cells, and have deficient CTL responses (18). Antibody-defi-
cient mice have been produced by disruption of the immu-
noglobulin 
 
m
 
 chain gene at the 
 
m
 
MT exon (19). In these
latter mice, peripheral B cells are absent, and no serum or
mucosal antibody responses can be generated (20).
In this investigation, mechanisms of vaccine-induced
protection against 
 
H. pylori
 
 were examined using mucosal
and parenteral immunization regimens with recombinant
urease in both wild-type and gene knockout mice. In wild-
type mice, mucosal immunization with urease plus LT
yielded higher levels of protection than did parenteral or
combination parenteral/mucosal regimens. Protection best
correlated with the density of T cells in the gastric mucosa
after challenge with 
 
H. pylori.
 
 An essential role for MHC
class II–dependent T cell responses in protection was deter-
mined using 
 
b
 
2
 
m and I-A
 
b
 
 knockout mice. In B cell
knockout mice, protection equivalent to that seen in im-
munized wild-type mice was demonstrated in the absence
of specific antibodies against urease. These results suggest a
central role of CD4
 
1
 
 T cell–dependent cell-mediated im-
munity in urease vaccine–induced protection of mice
against 
 
H. pylori
 
 infection.
 
Materials and Methods
 
Animals.
 
All procedures were conducted with approval of
the OraVax Institutional Animal Care and Use Committee. Spe-
cific pathogen–free, 8-wk-old outbred female Swiss-Webster mice,
inbred homozygous (
 
2
 
/
 
2
 
) and heterozygous (
 
1
 
/
 
2
 
) I-A
 
b
 
 gene
knockout mice, homozygous (
 
2
 
/
 
2
 
) and heterozygous (
 
1
 
/
 
2
 
)
 
b
 
2
 
m gene knockout mice, and wild-type (
 
1
 
/
 
1
 
) C57BL/6 mice
free from 
 
Helicobacter muridarum
 
 were obtained from Taconic
Farms, Inc. (Germantown, NY). Specific pathogen–free, 8-wk-
old 
 
m
 
MT (Igh 
 
2
 
/
 
2
 
) gene knockout mice back-crossed to the
C57BL/6 background and wild-type (
 
1
 
/
 
1
 
) C57BL/6J mice free
from 
 
Helicobacter
 
 spp. were obtained from The Jackson Lab. (Bar
Harbor, ME). Experimental groups contained 10–12 mice each.
 
Urease Expression and Purification.
 
Recombinant urease was
used as the model antigen in all studies and was expressed and pu-
rified from 
 
E. coli
 
 strain ORV214 as described previously (5). Na-
tive 
 
H. pylori
 
 urease was used as the coating antigen in ELISA im-
munoassays and was purified from 
 
H. pylori
 
 strain ATCC 43504
(American Type Culture Collection, Rockville, MD) as de-
scribed previously (5).
 
Adjuvants.
 
LT was obtained from Berna Products Corp.
(Coral Gables, FL). Alum was obtained as an aluminum hydrox-
ide gel (Rehydrogel
 
Ò
 
) from Reheis, Inc. (Berkeley Heights, NJ).
The glucosylamide Bay R 1005 [
 
N
 
-(2-deoxy-2-
 
l
 
-leucylamino-
b-
 
d
 
-glucopyranosyl)-
 
N
 
-octadecyldodecanamide acetate] (14, 21)
was provided by Bayer AG (Wuppertal, Germany).
 
Immunization Procedures.
 
Mice were immunized at weekly or
biweekly intervals with recombinant urease containing the appro-
priate dose of adjuvant (Table 1). For oral immunization, 25 
 
m
 
l of
vaccine was delivered into the mouth (5). For IN immunization,
10 
 
m
 
l of vaccine was applied onto the external nares of unanes-
thetized mice (15). For parenteral immunization, 100 
 
m
 
l of solu-
tion was injected by the s.c. route along the midline of the lower
back. 1 wk after the last immunization, blood samples were taken
from the retro-orbital sinus to measure the antiurease systemic
immune responses before challenge.
 
Immunization Regimens.
 
The immunization doses and sched-
ules for each study are outlined in Table 1. To determine the effi-
cacy of different adjuvants and routes of urease vaccine adminis-
tration, we compared mucosal immunization with parenteral
immunization in an outbred mouse model. The roles of MHC-I–
and MHC-II–restricted T cell responses in protection were ex-
amined in 
 
b
 
2
 
m and I-A
 
b
 
 gene knockout mice, and the role of B
cells and antibody in protection was examined in 
 
m
 
MT knockout
mice. In the adjuvant studies, urease plus LT was delivered by the
IN route to give a direct comparison with IN delivery of urease
without adjuvant. In the knockout studies, urease plus LT was
administered by the more traditional oral route. Both IN and oral
immunization with urease plus LT previously have been shown
to give comparable levels of protection and recruitment of gastric
T cells (3).
To determine the role of urease-specific serum IgG in protec-
tion, outbred Swiss-Webster mice were immunized by mucosal
and parenteral routes as described in Table 1. 1 wk after immuni-
zation, donor mice were bled, the sera pooled, and 2 ml was in-
jected by the i.p. route into seven recipient mice 2 d before 
 
H.
pylori
 
 challenge. Blood from recipient mice was sampled the next
day to confirm transfer of urease-specific antibodies.
 
H. pylori Growth Conditions and Challenge. A streptomycin-
resistant mutant of H. pylori strain X47-2AL was used for all chal-
lenge experiments. H. pylori strain X47-2AL (ORV2001) was orig-
inally isolated from a domestic cat (Dr. J.G. Fox, Massachusetts
Institute of Technology, Cambridge, MA) (22), and adapted to
Swiss-Webster mice by sequential in vivo passages (3). To pre-
pare the challenge inoculum, bacteria were grown on agar plates
for 2 d followed by 1 d in suspension (3). 2 wk after the last im-
munization, mice were challenged intragastrically via a 20-gauge
feeding needle with a 100-ml suspension of H. pylori strain X47-
2AL containing 107 CFU/ml. At z2 wk after challenge, mice
were killed and gastric tissue processed for urease activity, H. py-
lori culture, histology, or immunohistochemistry as described
below.
Serum Antibody Responses. Serum samples collected 7 d after
the last immunization were evaluated for urease-specific IgG,
IgG1, or IgG2a by indirect ELISA as described previously (3, 15).
Urease-specific IgM or IgA was detected by antibody-capture
ELISA. Plates were coated with 1 mg/ml goat anti–mouse IgM or
IgA (Southern Biotechnology Associates, Birmingham, AL); test
sera were added, followed by 2.5 mg/ml purified native H. pylori2279 Ermak et al.
urease, rabbit antiurease, and goat anti–rabbit IgG conjugated to
alkaline phosphatase (Southern Biotechnology Associates). ELISA
plates were developed with p-nitrophenyl phosphate (Sigma
Chemical Co., St. Louis, MO) and absorbance read at OD405
with a Vmax microplate reader (Molecular Devices Corp., Sunny-
vale, CA). The concentrations of urease-specific serum IgG1 and
IgG2a were calculated using standard curves generated by titrating
pooled high-titer sera (23). The results were expressed as U/ml,
and the IgG1:IgG2a ratio was calculated for each mouse. Absor-
bance values were converted to specific antibody measurements
using standard curves generated with SOFTmax 881 software
(Molecular Devices Corp.).
Gastric Tissue Analyses. The stomach was dissected along the
lesser curvature and divided into strips for urease activity, H. py-
lori culture, histopathology, or immunohistochemical analyses.
For histopathology, a longitudinal segment including the antrum
and corpus plus a piece of attached intestine was fixed in 10%
neutral buffered formalin, embedded in paraffin, and sectioned
at 5 mm. For immunohistochemistry, gastric segments were
mounted on a 3-mm slice of spleen by wrapping the mucosa
around the outer capsule of the spleen with the gastric mucosa
facing outwards. Each piece of tissue was then mounted in
O.C.T. compound (Sakura Finetek USA Inc., Torrance CA),
and quick-frozen in Freon 22 cooled to its freezing point by
liquid nitrogen. The spleen served as a positive control for each
lymphocyte subset tested. In the knockout studies, a 5-cm-long
segment of the intestine was frozen in O.C.T. by coiling the in-
testine around itself to form a 1–1.5-cm disk.
Urease Activity. The presence of H. pylori in gastric tissue was
assessed by urease activity measured spectrophotometrically after
4 h of incubation using a colorimetric urease test, as described
previously (3, 15).
Quantitative Culture of H. pylori from Gastric Tissue. An antral
strip was placed in 1 ml Brucella broth and homogenized until
the tissue was completely disrupted. 10-fold serial dilutions were
then prepared and plated onto Helicobacter-selective agar, as de-
scribed above. Bacterial counts were determined after 5 d of
growth in a 7% CO2 incubator at 378C.
Histopathology. Histological sections from adjuvant studies
and MHC-II and MHC-I knockout studies were evaluated by a
pathologist blinded to the sample code (randomized histological
sections of gastric mucosa) as described previously (11). H. pylori
organisms in gastric sections were made visible with a modified
Steiner silver stain (Sigma Chemical Co.). The density of H. py-
lori per longitudinal section from the intestine through the entire
antrum and corpus was scored as follows: 0, no bacteria; 1, 1–5
foci containing one or more bacteria; 2, 5–10 foci; 3, 10–20 foci;
and 4, .20 foci.
Gastritis and epithelial alterations were evaluated on hematox-
ylin and eosin (H & E) stained sections as described previously
(11). For gastritis, sections were scored from zero to four based
upon the intensity of the infiltration of lymphocytes, plasma cells,
and neutrophils. The degree of epithelial change was scored simi-
larly based on the loss of parietal cells, hyperplasia of the surface
epithelium, and the presence of microabscesses or cystic glands.
Immunohistochemistry of Gastric Tissue. Cryosections were blocked
with avidin–biotin-blocking reagents (Vector Laboratories Inc.,
Burlingame, CA), and endogenous peroxidase activity blocked
with 0.03% H2O2 and 0.01% sodium azide in PBS. The sections
were incubated with rat mAbs against mouse CD4 (clone RM4-
Table 1. Vaccine Schedule for Protection Studies
Group
No. and route of
immunizations* Urease dose Adjuvant dose
Adjuvant and route study in Swiss-Webster mice‡ mg mg
Urease/no adjuvant 14 daily IN 25 —
Alum 3 s.c. 10 200
Bay 3 s.c. 10 400
LT/Alum 1 IN/2 s.c. 25/10 1/200
LT/Bay 1 IN/2 s.c. 25/10 1/400
LT 3 IN 25 1
MHC-class I and class II study in C57BL/6 mice§
Alum 3 s.c. 10 200
LT 4 weekly oral 25 1
Passive transfer study in Swiss-Webster mice
Urease/no adjuvant 15 daily IN 25 —
Alum 3 s.c. 10 200
LT 3 IN 25 1
mMT study in C57BL/6J mice‡
Alum 3 s.c. 10 200
LT 3 oral 25 1
*Immunizations given biweekly unless otherwise noted; controls were untreated.
‡Included 10 mice per group.
§Included 10 (1/1) and (2/2) mice and 5 (1/2) mice per group.2280 Protection against Helicobacter pylori Infection in the Absence of Antibodies
5), CD8a (clone 53-6.7), CD103 (aE-integrin) (clone M290),
b7-integrin (clone M293), CD45R (B220) (clone RA3 6B2), IgA
(clone R5-140), IgM (clone R6-60.2), CD11b (Mac-1) (clone
M1/70), or Ly-6G (clone RB6-8C5) (reactive with neutrophils)
(PharMingen, San Diego, CA). Sections were then incubated
with biotinylated rabbit anti–rat IgG (Vector Laboratories Inc.),
followed by horseradish peroxidase conjugated to an avidin–bio-
tin complex (ABC-Elite Kit; Vector Laboratories Inc.), diami-
nobenzidine, and methyl green. Control sections were incubated
without primary mAb. Urease-specific antibody–containing cells
(urease-ACC) were detected by an avidin–biotin glucose oxidase
procedure, as described previously (3). The number of positive
cells was counted in 0.5-mm segment lengths of gastric mucosa
and expressed per mm2 field as described previously (11).
Flow Cytometric Analyses of Lymphocyte Populations. Peripheral
blood, spleen, and intestinal intraepithelial lymphocytes (IEL)
were examined for depletion of T cells in knockout mice using
rat mAb against mouse CD4 (clone RM4-5), CD8a (clone 53-
6.7), CD103 (aE-integrin) (clone M290), CD90 (Thy-1.2) (clone
30-H12), CD45 (clone 30-F11), CD45R (B220) (clone RA3
6B2), IgM (clone R6-60.2), I-Ab (Ab
b) (clone 25-9-17), or H-2Db
(clone KH95) (PharMingen) as described previously (11, 24).
The stained lymphocytes were analyzed (10,000 cells) using an
Epics XL (Coulter Corp., Miami, FL).
Statistics. Statistical analyses were performed with either JMPÔ
or Graphpad PrismÔ software using Wilcoxon/Kruskal-Wallis (rank
sums) test for continuous or ordinal variables, or linear regression.
Results
Role of Adjuvant and Route of Immunization in Protection 
of Outbred Mice
Protection against H. pylori Infection. Levels of protection
were determined by urease activity or quantitative culture
of gastric tissue in a study using five different adjuvant regi-
mens administered with urease (plus controls) to determine
whether correlates of protection could be identified (Fig.
1). Unimmunized mice and mice receiving daily IN urease
immunization without adjuvant were highly infected with
geometric mean CFUs of z5.0 3 104–1.5 3 105 per gas-
tric segment at 14 d after challenge. The greatest level of
protection was observed in mice given urease plus LT by
the IN route; the geometric mean H. pylori density (3.6 3
102) was 100–1,000-fold lower than in unimmunized mice
or mice receiving the same regimen of urease without ad-
juvant (P , 0.01 versus controls; Wilcoxon/Kruskal-Wallis
rank sums test). Parenteral administration of the same dose
and regimen of urease plus either alum or Bay adjuvants re-
sulted in partial protection characterized by greatly reduced
gastric urease activity (P , 0.01) but ,10-fold decrease in
H. pylori density by culture (significance achieved versus IN
per day controls, P , 0.02; but not versus unimmunized
controls). A combined regimen of mucosal priming with
urease plus LT followed by parenteral boosting with urease
plus alum or Bay gave intermediate levels of protection be-
tween urease plus LT and parenteral-only regimens (10–
100-fold decrease in H. pylori versus controls, P , 0.01).
Effects on Gastric Mucosa. Histopathologic evaluations of
gastritis and epithelial change were performed on H & E
sections of gastric mucosa from mice that received urease
plus LT, urease plus alum, or no immunization, and were
then challenged with H. pylori. As reported elsewhere (14),
immunization and protection was associated with increased
recruitment of immune cells to the gastric mucosa in com-
parison with controls (each group, P  , 0.01). The in-
creased cellular infiltrate was accompanied by only a slight
increase in epithelial change in either the antrum or corpus
(mean epithelial score in the corpus increased from 0 in
controls to 1 in urease plus LT immunized mice, P  ,
0.01).
Recruitment of T and B Cells to Gastric Tissue after Chal-
lenge. Previous studies demonstrated that significant re-
cruitment of CD41 and CD81 cells occurs in the gastric
mucosa of immunized mice after H. pylori challenge (3). In
this study, we examined the regional localization of cells af-
Figure 1. Protection against H. pylori infection in Swiss-Webster mice
immunized with recombinant urease using nonprotective, partially pro-
tective, and highly protective adjuvant and route combinations. (A) Gas-
tric urease activity. (B) H. pylori CFUs from gastric mucosa. All groups
were challenged with H. pylori. (Ctrl) Control mice were untreated. (IN/
day) IN urease daily over 14 d without adjuvant. (Al) Three biweekly s.c.
immunizations with urease plus alum. (Bay) Three biweekly s.c. immuni-
zations with urease plus Bay R 1005. (LT/Al) One IN immunization
with urease plus LT followed by two s.c. immunizations with urease plus
alum. (LT/Bay) One IN immunization with urease plus LT followed by
two s.c. immunizations with urease plus Bay. (IN LT) Three biweekly IN
immunizations with urease plus LT. Data points are from individual mice.
In A, the bar represents the arithmetic mean of each group. In B, the bar
represents the geometric mean CFU. Al and Bay groups showed signifi-
cant protection after challenge as inferred from urease activity (P , 0.01),
but at most a 10-fold decrease in bacterial density as determined by quan-
titative culture (Al, P 5 0.05, and Bay, not significant, versus unimmu-
nized controls; Al and Bay, P , 0.02, versus IN/day group). LT/Al and
LT/Bay showed greater protection than Al or Bay alone (P , 0.04). IN
LT was more protective than LT/Al (P , 0.03) or LT/Bay (P , 0.01).
Wilcoxon/Kruskal-Wallis (rank sums) test.2281 Ermak et al.
ter challenge. The highest density of cells localized at the
junction between the antrum and corpus (Fig. 2 a). For ex-
ample, immunized mice had three to four times as many
CD41 cells in the junction region as in the antrum or cor-
pus. In histological sections of gastric tissue from unimmu-
nized mice examined in preliminary studies, the junction
region was also the area where most H. pylori were located
(data not shown). Therefore, quantitative analyses of gastric
lymphocytes focused on this region.
The density of gastric T cells, IgA1 plasma cells, and ure-
ase-ACC was determined for each group of mice. CD41
cells were the most numerous of any lymphocyte subset,
averaging a fivefold increase in density over unimmunized
controls, and were found along the muscularis mucosa and
in the lamina propria between gastric pits (Fig. 2 b). The
density of T cells varied as a function of immunization reg-
imen (Fig. 3, A and B) and strongly correlated with the
level of protection (CD41 cells, r2 5 0.956; CD81 cells, r2 5
0.947) (Fig. 3, D and E). Nonprotective daily IN urease
immunization without adjuvant resulted in no gastric T
cells, whereas immunization with urease plus adjuvant by
any route produced a significant increase in gastric T cells
(all groups, P , 0.01). IN immunization with urease plus
LT induced the greatest number of gastric T cells.
IgA1 cells were also most numerous in the urease plus
LT group, increased in the nonprotective regimen of IN
urease without adjuvant (P , 0.04), and were somewhat
variable in animals receiving the parenteral and combina-
tion regimens (Fig. 3 C). IgA1 cells also showed a weak
positive correlation with the level of protection (r2  5
0.690) (Fig. 3 F). Urease-ACC were detected in mice re-
ceiving urease plus LT (1–2 cells/mm2 field in mice receiv-
ing urease plus Bay, LT/alum, LT/Bay, or LT alone), but
no cells were detected in control, urease daily without ad-
juvant, or urease plus alum groups.
Urease-specific IgG1 and IgG2a Levels as Surrogate Markers for
Th2:Th1 Responses. Urease-specific antibody levels were
analyzed to determine if IgG1:IgG2a ratios correlated with
protection (3, 12, 14). Daily IN administration of urease
without adjuvant and parenteral immunization with alum
or Bay produced higher IgG1 than IgG2a levels, whereas
immunization with urease plus LT produced equivalent
levels of IgG1 and IgG2a (Table 2). The ratio of urease-spe-
cific IgG1 to IgG2a showed a positive correlation with pro-
tection (r2 5 0.703), with a ratio of 1 being associated with
the greatest protection (urease plus LT). This correlation
suggested that a balanced Th2:Th1 response might be im-
portant for the high level of protection observed after im-
munization with urease plus LT.
Figure 2. Localization of CD41 T cells in the gastric mucosa of urease-
immunized,  H. pylori–challenged mice. (a) Low-power field of gastric
mucosa mounted on a slice of spleen (S). CD41 cells localized at the
junction region (J) of a mouse receiving s.c. urease. A, Antrum; C, cor-
pus; and M, muscularis externa. (b) High-power field of CD41 T cells in
the gastric mucosa of a mouse receiving IN urease plus LT. T cells local-
ized in the lamina propria between gastric pits and adjacent to the muscu-
laris mucosa (arrowheads). Original magnifications: a, 330; b, 375.
Figure 3. T and B cell subsets in the gastric mucosa of H. pylori chal-
lenged mice as a function of adjuvant and route of administration. (A–C)
Quantitative evaluation of CD41, CD81, and IgA1 cells. Mice immu-
nized with urease plus adjuvant showed significant increases in T and B
cells relative to unimmunized controls. IN/day group had no increase in
T cells but did have increased IgA1 cells (P , 0.04). Some combination
regimens were not significantly different from single adjuvant regimens.
(D–F) Correlation of CD41 cells, CD81 cells, and IgA1 cells with geo-
metric mean H. pylori CFUs.2282 Protection against Helicobacter pylori Infection in the Absence of Antibodies
Protection in I-Ab (2/2) and b2m (2/2) Knockout Mice
Effect of Immunization on H. pylori in Gastric Tissue after
Challenge. Wild-type,  b2m (2/2), and I-Ab ( 2/2)
C57BL/6 mice received urease administered either orally
with LT, parenterally with alum, or were not immunized
before challenge. The doses and regimens are outlined in
Table 1. Analysis of gastric tissue revealed that wild-type
(1/1) and b2m (2/2) mice receiving urease plus LT had
little detectable gastric urease activity and a .100-fold de-
crease in geometric mean CFUs as compared with unim-
munized controls (P , 0.01) (Fig. 4). Subcutaneous immu-
nization with urease plus alum resulted in a significant
decrease in gastric urease activity (Fig. 4 A) and a fivefold
decrease in the bacterial density of wild-type (1/1) mice
(P 5 0.02) (Fig. 4 B), but had no protective effect in b2m
(2/2) or heterozygous (1/2) strains (Fig. 4). Oral immu-
nization of both wild-type and b2m (2/2) mice with ure-
ase plus LT clearly gave superior protection in comparison
to parenteral immunization with alum (P , 0.02).
Neither mucosal nor parenteral immunization regimens
were effective in protecting I-Ab (2/2) knockout mice as
determined by gastric urease activity and quantitative cul-
ture (Fig. 4). The geometric mean bacterial densities of im-
munized mice were no different from those of unimmu-
nized controls. Furthermore, H. pylori infection was not
enhanced in the absence of the host MHC II–restricted re-
sponses of control I-Ab ( 2/2) mice in comparison to
wild-type mice (Fig. 4).
Antibody Responses to Urease Immunization. An analysis of
urease-specific serum IgG, IgM, and IgA indicated systemic
immune responses to urease in mice from all immunized
groups except the I-Ab (2/2) knockout mice, which did
not have detectable antibody responses (data not shown).
b2m (2/2) knockout mice had reduced serum IgG titers
after immunization when compared with wild-type mice,
as well as equivalent or lower levels of serum IgM and IgA.
Effects on Gastric Mucosa. As in outbred mice, immuni-
zation and challenge in wild-type and b2m (2/2) mice
but not I-Ab (2/2) mice was associated with increased
lymphocyte recruitment to the gastric mucosa, as deter-
mined by gastritis scores obtained from H & E sections
(data not shown). Wild-type (1/1) mice immunized with
urease plus LT had minimal loss of parietal cells (mean cor-
pus epithelial score of 1.1, range 0–2) relative to controls
(mean of 0.2, range 0–2) (P , 0.04), whereas a more sub-
stantial loss of parietal cells was seen in b2m (2/2) mice
receiving the same regimen (mean score of 2.4, range 1–3)
(P  , 0.01 versus controls). Wild-type and b2m (2/2)
mice immunized with urease plus alum, and the unpro-
tected I-Ab (2/2) mice immunized by either regimen, had
no epithelial change relative to controls.
T and B Cells in Gastric Tissue. The densities of CD41,
CD81, and IgA1 cells in the gastric mucosa were evaluated
as indicators of T and B cell activity in response to immu-
nization and challenge. In addition, the densities of CD81
and CD1031 (aE-integrin1) cells were used as indicators of
gastric IEL. Unimmunized controls had few T or B cells in
the gastric mucosa 2 wk after H. pylori challenge. Signifi-
Table 2. Urease-specific Serum IgG1 and IgG2a Levels by 
Immunization Regimen
Group
IgG1
(median)
IgG2a
(median)
IgG1:IgG2a
ratio*
(median)
U/ml U/ml
IN/day 2.61 3 106 5.71 3 104 41
Alum 7.03 3 107 1.31 3 106 43
Bay 5.35 3 107 3.20 3 106 38
LT/Alum 3.88 3 107 2.66 3 107 1.9
LT/Bay 4.82 3 107 6.73 3 106 10
LT 2.01 3 107 9.61 3 106 1
*Median IgG1:IgG2a ratio from individual mice; not the ratio of median
IgG1 to median IgG2a.
Figure 4. Protection against H. pylori infection in wild-type (1/1),
b2m (2/2), and I-Ab (2/2) knockout mice in response to challenge.
(A) Gastric urease activity. (B) H. pylori CFUs from gastric mucosa. All
groups were challenged with H. pylori. (Ctrl) Control mice received LT
but no urease. (Al) Three biweekly s.c. immunizations with urease plus
alum. (LT) Four weekly oral immunizations with urease plus LT. Data
points are from individual mice. In A, the bar represents the arithmetic
mean of each group. In B, the bar represents the geometric mean CFU.
b2m (2/2) knockout mice receiving urease plus alum were not pro-
tected. Not shown, wild-type heterozygous (1/2) mice were protected
after urease plus LT but not after urease plus alum. Lack of protection in
these mice may reflect differences among (1/1), (1/2), and (2/2)
strains.2283 Ermak et al.
cant increases in CD41, CD81, CD1031, and IgA1 cells
were seen in b2m (2/2) and wild-type (1/1) mice im-
munized with urease plus LT (P , 0.05) (Fig. 5).
Smaller increases in T and B cells were seen after immu-
nization with urease plus alum (all groups, P , 0.05, ex-
cept CD41 cells in b2m/alum group and IgA1 cells in
b2m/alum group) (Fig. 5). b2m (2/2) knockout mice had
reduced CD81 and CD1031 cells in the gastric mucosa af-
ter oral immunization with urease plus LT relative to wild-
type mice (P , 0.05, except CD81 cells did not achieve
significance). Most CD81 and CD1031 cells in the gastric
mucosa of b2m (2/2) mice were within the epithelium,
suggesting that they were IEL.
The lack of protection in I-Ab (2/2) knockout mice
was accompanied by an absence of T or B cells recruited to
the gastric mucosa after challenge. Although some CD41 T
cells were present in peripheral blood, spleen, Peyer’s
patches, and intestinal lamina propria of I-Ab (2/2) mice,
CD41 cells and all other T and B cell subsets in the gastric
mucosa were similar to those seen in unimmunized control
mice (Fig. 5).
Role of Serum IgG in Protection
The ability of parenteral immunization to afford protec-
tion against H. pylori raised the possibility that serum anti-
bodies could play a role in bacterial clearance. This conclu-
sion was supported by studies in I-Ab (2/2) mice which
had no antibody response to urease and were not protected
against challenge. In an effort to clarify the contribution of
circulating antiurease antibodies to protection, we tested
whether immunity could be transferred to naive mice by
serum, as described in Materials and Methods and Table 1.
Groups of donor mice were immunized with either a pro-
tective mucosal regimen (IN urease plus LT), a protective
parenteral regimen (urease plus alum), a nonprotective mu-
cosal regimen (intranasal urease without adjuvant), or were
untreated. After passive transfer of sera, recipient mice had
protective levels of urease-specific serum IgG similar to
those of actively immunized mice before challenge (data not
shown). Despite the presence of high levels of urease-spe-
cific IgG in recipient mice, including mice receiving serum
from donor mice immunized according to the protective
mucosal or parenteral regimens, no protection was ob-
served in any mice after challenge.
Protection against H. pylori Infection in mMT
Knockout Mice
Effect of Immunization on H. pylori Infection. The inabil-
ity of immune sera to passively confer protection from H.
pylori infection to naive mice demonstrated that circulating
antibodies to urease alone played a minor, if any, role in
protection. To elucidate the contribution of local antibody
responses in the gastric mucosa, B cell–deficient mice were
used. Wild-type (1/1) and mMT (2/2) C57BL/6J mice
received either oral or parenteral immunization with ure-
ase, as did the MHC-I and MHC-II knockout mice (Table
1). Oral immunization with urease plus LT decreased the
gastric urease activity to baseline levels and reduced the
density of H. pylori by more than 100-fold in both wild-
type and mMT (2/2) mice after challenge (both assays, all
groups, P , 0.01 versus controls) (Fig. 6). Parenteral im-
munization with urease plus alum reduced the density of
H. pylori 10-fold in wild-type mice (P , 0.03) and fivefold
in mMT (2/2) mice (not significant) and decreased gastric
urease activity to baseline levels in more than half of the
mice in both groups (Fig. 6).
Antibody Responses to Urease Immunization. No urease-spe-
cific serum IgG, IgM, or IgA responses to urease were
detected in mMT (2/2) mice after oral immunization
with urease plus LT or parenteral immunization with ure-
Figure 5. Quantitative phenotypic analysis of the cellular infiltrate in
the gastric mucosa of wild-type (1/1), b2m (2/2), and I-Ab (2/2)
mice challenged with H. pylori. (A) CD41 cells. (B) CD81 cells. (C)
CD1031 (aE-integrin1) cells. Most CD81 and CD1031 cells in b2m (2/2)
mice were gastric IEL. (D) IgA1 cells. All wild-type and b2m (2/2)
groups had P , 0.05 versus controls, except the following alum groups:
b2m CD41 cells, wild-type and b2m IgA1 cells. I-Ab ( 2/2) mice
showed no increase in T or B cells after immunization and challenge.
Figure 6. Protection against
H. pylori infection in wild-type
(1/1) and mMT (2/2) knock-
out mice. (A) Gastric urease ac-
tivity. (B) H. pylori CFUs from
gastric mucosa. All groups were
challenged with H. pylori. (Ctrl)
Mice were not immunized. (Al)
Three biweekly s.c. immuniza-
tions with urease plus alum. (LT)
Three biweekly oral immuniza-
tions with urease plus LT. Data
points are from individual mice.
In  A, the bar represents the
arithmetic mean of each group.
In B, the bar represents the geo-
metric mean CFU. LT groups,
P  , 0.01 versus unimmunized
controls. In alum groups, only
wild-type mice achieved a signif-
icant reduction in bacterial den-
sity (P , 0.02 versus unimmu-
nized controls).2284 Protection against Helicobacter pylori Infection in the Absence of Antibodies
ase plus alum (data not shown). In contrast, significant in-
creases in specific antibody levels were found in wild-type
(1/1) mice immunized by all regimens. These results con-
firmed the defect in antibody production in mMT (2/2)
mice and demonstrated that protection against H. pylori in-
fection can be achieved in the absence of specific serum an-
tibodies to urease.
T Cells, B Cells, and Nonlymphoid Cells in Gastric Tissue.
In light of the unexpected observation of protection in the
absence of serum antibodies after oral immunization with
urease, we examined the local gastric lymphoid and non-
lymphoid cell populations that might account for immune
clearance. Enumeration of T and B cell subsets revealed
that the densities of CD41 in the gastric mucosa of wild-
type and knockout mice that received either urease plus LT
or urease plus alum were significantly higher than those in
unimmunized mice (wild-type, P  , 0.01; mMT, P ,
0.05) (Fig. 7). An equivalent level of CD81 cells was seen
in both immunized wild-type and mMT mice, but the dif-
ference relative to nonimmunized controls was not signifi-
cant in the mMT mice. IgA1 and IgM1 cells were absent in
the stomach of knockout but not wild-type mice (Fig. 7).
Immunohistochemical staining of the spleen, intestine,
and Peyer’s patches was performed in uninfected mice to
identify sources of T and B cells in the knockout mice. No
IgM1 or IgA1 B cells were detected in either the spleen or
Peyer’s patches, and no IgA1 plasma cells were found in
the lamina propria of the intestine. However, CD41 and
CD81 cells were seen in the T cell areas of the spleen and
Peyer’s patches (composed of tiny domes and flattened T
cell regions), and in the lamina propria and epithelium of
the intestine.
To determine whether nonlymphoid populations were
recruited to the gastric mucosa after challenge, macro-
phages (CD11b1 cells) (25, 26) and neutrophils (Ly-6G1
cells) (27, 28) were enumerated. CD11b (Mac-1) is ex-
pressed on macrophages and dendritic cells and may also be
present on activated neutrophils (26). Wild-type and
knockout mice showed higher levels of CD11b1 and Ly-
6G1 cells in the junction region of the gastric mucosa after
immunization and in comparison with controls (Fig. 7).
CD11b1 macrophages were the most numerous cell type
after CD41 T cells.
Discussion
Vaccination against H. pylori is an important goal in the
prevention and treatment of gastroduodenal diseases, in-
cluding ulcers and stomach cancer. Despite the proven
ability of immunization to prevent or reduce Helicobacter in-
fection in murine models, the precise mechanisms of pro-
tection have remained obscured by the numerous immu-
nological pathways stimulated. Mucosal immunization with
Helicobacter extracts or purified recombinant proteins gener-
ates antigen-specific serum, salivary, and intestinal antibody
responses as well as cellular immunity (3, 5, 12, 13, 29).
Furthermore, after immunization and challenge, gastric IgA
and T cell responses can be measured (3, 5, 6). Since H.
pylori is largely an extracellular pathogen of the gastric mu-
cosa, it was reasoned that secretory IgA might play an
important role in protection through diminished bacterial–
mucus or –epithelial cell interactions (5, 30). In this study,
we examined mechanisms of protection using different ad-
juvants and routes of administration and a single H. pylori
candidate vaccine antigen in several murine knockout
models with the goal of further defining aspects of cell- and
antibody-mediated immunity essential for clearance of H.
pylori.
By comparing various prophylactic immunization schemes,
including mucosal, parenteral, or combination regimens,
we consistently achieved the highest level of protection by
mucosal immunization with urease plus LT, which de-
creased the gastric bacterial load 100-fold or more after
challenge compared with controls. A combined protocol
of mucosal and parenteral immunization conferred a level
of protection close to that of mucosal immunization. Pro-
tective efficacy was evaluated by quantitative culture of
H. pylori, which has been shown (3) to be more sensitive
than either measurement of gastric urease activity or histo-
logical enumeration of bacteria (3, 8, 31). The H. pylori
Figure 7. Quantitative evaluation of T cells, B cells, macrophages, and
neutrophils in the gastric mucosa of wild-type (1/1) and mMT (2/2)
mice challenged with H. pylori. (A) CD41 cells. Wild-type, both groups
P , 0.01 versus controls. mMT, both groups P 5 0.05 versus controls.
(B) CD81 cells. Wild-type, both groups P , 0.01 versus controls. mMT
mice, both groups not significant versus controls. (C) IgM1 cells (mostly
small lymphocytes). (D) IgA1 cells (mostly plasma cells). (E) CD11b1
cells (macrophages). Wild-type, LT group, P , 0.03, alum group not sig-
nificant versus controls. mMT, LT group not significant, alum group, P 5
0.02 versus controls. (F) Ly-6G1 cells (neutrophils). Wild-type, both
groups not significant versus controls. mMT mice, LT group, P , 0.05;
alum group, P 5 0.02 versus controls.2285 Ermak et al.
strain X47-2AL, originally isolated from a domestic cat
(22), preferentially colonized the corpus–antrum junction
region of the mouse stomach, a similar distribution to that
of the human-derived H. pylori Sydney (SS1) strain (31).
The requirement for LT with mucosal immunization was
clear; no detectable protective activity could be measured
in the absence of mucosal adjuvant when urease was ad-
ministered by a daily IN regimen or in the form of weekly
doses (15). Parenteral immunization with urease plus alum
or Bay adjuvant showed less protection by comparison,
demonstrating significant protection by gastric urease activ-
ity, but yielding at most a 10-fold reduction in bacterial
burden after challenge.
Because a range of protective efficacy was observed with
the immunization regimens tested, we examined several
immunological readouts for correlation with protection.
Previous analyses of the levels of urease-specific antibodies
in sera and mucosal secretions after immunization with
urease failed to identify a single isotype-restricted response
which correlated with protection (3). However, the analy-
sis of antigen-specific IgG1/IgG2a ratios as markers of Th
activity in this investigation and a comparative study of sev-
eral different parenteral adjuvants (14) determined that a
more balanced (i.e., 1:1) profile was associated with greater
protection, suggesting that the ability to stimulate both Th1
and Th2 responses was important for protection. These ob-
servations supported the emerging concept from vaccina-
tion studies that cell-mediated immunity is required for
clearance of H. pylori from the murine gastric mucosa.
We focused our attention on the constituents of the cel-
lular infiltrate that are present in the gastric mucosa after
immunization and challenge. A common feature of the in-
filtrate was its preferential localization at the corpus–antrum
junction, which coincided with the distribution of H. py-
lori. Interestingly, in humans, the junction region is also the
site where intestinal metaplasia, gastric atrophy, and cancer
are often found (32). When comparing the constituents of
the infiltrate elicited by the various regimens, we found
that certain immunization schemes stimulated recruitment
of distinct cellular profiles in response to H. pylori chal-
lenge. For example, the nonprotective regimen of IN ure-
ase immunization without adjuvant (15) induced B cells
but few T cells to the gastric mucosa. In contrast, IN im-
munization with urease plus LT was followed by extensive
recruitment of both T and B cells to the gastric mucosa.
Furthermore, the density of the local infiltrate after immu-
nization and challenge correlated with enhanced bacterial
clearance. Because the appearance of the cellular infiltrate
was dependent on prior exposure to antigen, required H.
pylori challenge, and could be modulated by adjuvants, an
antigen-specific cellular response after local stimulation
with  Helicobacter-associated urease is the likely mechanism
responsible for the extensive cellular trafficking to the gas-
tric mucosa. Despite the recruitment of mononuclear cells
to the gastric mucosa after protective vaccination and H.
pylori challenge, extensive epithelial damage was not found
in wild-type mice. At this time, it is not clear how these
observations in the murine model will translate to humans,
since it remains to be determined whether vaccination will
limit both infection and pathology. In unimmunized hu-
mans, the severity of inflammation correlates with the level
of infection (33–35), suggesting that controlling infection
may also reduce inflammation.
Use of MHC-I and MHC-II knockout mice has been
instrumental in elucidating mechanisms of immunity and
vaccine-induced protection to a number of viruses, bacte-
ria, and parasites (36–38). Using these research tools, we
were able to demonstrate that protection against H. pylori
can be achieved in MHC-I–deficient mice receiving oral
urease plus LT. Mice that are lacking b2m are deficient in
CD8ab1 T cells and fail to generate cytotoxic T cell re-
sponses (39, 40). This finding strongly suggests that MHC-I–
restricted CD8ab1 cell responses do not play a major role
in protection against murine H. pylori infection. Because
CD81 cells typically contribute to host defenses against
viruses and intracellular bacteria (36), it is not surprising
that these cells are not key players against this extracellular
organism. The present study does not rule out a possible
role of MHC-I in protection afforded by parenteral (alum)
immunization, nor does it exclude a possible role of MHC-I–
independent CD81 cell responses such as that performed
by gastric CD8aa1 IEL, which differentiate independently
of MHC-I (39–41). However, considering the relatively
low density of these cells in comparison to CD41 cells or
macrophages it seems likely that they are not the principal
cellular component involved in protection based upon ure-
ase vaccination.
In contrast to MHC-I–deficient mice, immunization and
challenge of MHC-II knockout mice revealed a profound
defect in the ability of immunization to afford protection.
The lack of protection was associated with an absence of
CD41 and CD81 T cells and IgA1 B cells in the gastric mu-
cosa. Although the MHC class II–deficient mice did not
mount a protective immune response, the absence of detect-
able urease-specific antibodies in sera and IgA1 cells in the
gastric mucosa of these mice did not clarify the relative roles
of antibodies and CD41 T cells as effectors of protection.
In an effort to determine the contribution of circulating
antibodies to protection, we performed passive transfer
studies using immune sera from mice vaccinated via mu-
cosal or parenteral routes. Despite high antibody titers to
urease in recipient mice, no detectable protection after
Helicobacter challenge was observed, demonstrating that an-
tigen-specific circulating antibodies play little or no role in
protection in this model. However, these experiments
could not definitively rule out the potentially protective
role of locally synthesized antibodies. Our previous studies
using mucosal immunization suggested that urease-specific
IgA cells recruited to the lamina propria secreted antibody
into the gastric pits (3, 5), and thus theoretically could play
a role in immune clearance. It has also been proposed that
local IgG antibodies in the gastric mucosa may play a role
in protection (10). Conflicting data with these studies
showing that mice deficient in IgA were protected against
H. felis challenge (42) further contributed to the confusion
as to the role of antibodies in protection against Helicobacter.2286 Protection against Helicobacter pylori Infection in the Absence of Antibodies
To define the role of humoral immunity in protection from
H. pylori more precisely, we used the mMT (2/2) mouse
model of B cell and antibody deficiency. This model has
been instrumental in determining the role of humoral im-
munity in clearance of infectious diseases (43–45). Immu-
nization followed by challenge of mMT (2/2) mice re-
vealed, unexpectedly, that they were capable of mounting a
protective response to H. pylori which was indistinguishable
from that of wild-type mice. However, the results obtained
with knockout mice do need to be interpreted with cau-
tion, as it is known that ablation of specific immune func-
tions can result in compensation by alternative pathways
(20, 43). Nonetheless, these results demonstrated that clear-
ance of H. pylori from the gastric mucosa can occur by anti-
body-independent mechanisms and suggest that, in normal
mice, neither gastric IgA (3) nor IgG antibodies (10) play
an essential role in protection after immunization with urease.
In the absence of demonstrable antibody responses in
mMT (2/2) mice, we enumerated various cell popula-
tions present in the stomach that were associated with pro-
tection. We found that CD41 T cells and CD11b1 macro-
phages were the most numerous cells, followed by Ly-6G1
neutrophils. The local density of macrophages may in part
be due to a compensatory component of the mMT (2/2)
background, since these mice have been reported to have
higher levels of macrophages relative to wild-type mice
(20, 43). Nonetheless, the requirement of CD41 T cells for
protection, as demonstrated by their absence in the gastric
mucosa of I-Ab (2/2) mice after immunization and chal-
lenge, in conjunction with their relative abundance in the
stomach of immunized protected wild-type and B-cell–
deficient mice, implicates Th cells as primary mediators of
vaccine-induced protection in the mouse model. This con-
clusion is supported by adoptive transfer of protection
against H. felis with antigen-specific CD41 T cells (12).
The precise mechanisms responsible for bacterial clearance
in the H. pylori mouse model remain undefined and under
investigation.
In conclusion, this study demonstrated that, in a murine
model, protection against H. pylori can be achieved by ure-
ase in the absence of B cells and antibodies but requires
MHC class II CD41 T cell responses. These findings reveal
a previously unreported cell-mediated mechanism of im-
mune clearance of a predominantly intraluminal pathogen
of the gastrointestinal tract. We cannot predict that a simi-
lar mechanism is responsible for protection after vaccina-
tion with other Helicobacter antigens, either during long-
term challenge or after therapeutic immunization. Future
studies will determine whether this is a universal mecha-
nism used in these various settings.
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